Antibody–drug conjugates (ADCs) represent an emerging immunotherapeutic modality for tumors that frequently metastasize to the brain [58, 59], such as HER2 + breast cancer (Fig. 1) [60, 61]. This evidence concerns the gene ERBB2 and breast carcinoma.